Milestone Pharmaceuticals (MIST) Share-based Compensation (2018 - 2026)

Milestone Pharmaceuticals' Share-based Compensation history runs 9 years deep, the most recent figure standing at $1.3 million for Q1 2026.

• Quarterly Share-based Compensation fell 82.68% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.7 million (up 4.15% YoY) and the FY2025 annual result came in at $7.5 million, up 29.17% from the prior year.
• Share-based Compensation was $1.3 million for Q1 2026 at Milestone Pharmaceuticals, down from $3.6 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $18.6 million in Q3 2022 and bottomed at $1.3 million in Q1 2026.
• A 5-year average of $4.8 million and a median of $2.4 million in 2022 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2022 — Share-based Compensation slumped 89.72% — and 2023, when it jumped 571.92%.
• Milestone Pharmaceuticals' Share-based Compensation stood at $2.1 million in 2022, then declined by 12.41% to $1.9 million in 2023, then slipped by 21.47% to $1.5 million in 2024, then surged by 140.98% to $3.6 million in 2025, then sank by 63.91% to $1.3 million in 2026.
• Business Quant data shows MIST's Share-based Compensation at $1.3 million in Q1 2026, $3.6 million in Q4 2025, and $4.4 million in Q3 2025.